Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on September 9, 2008
JNCI Journal of the National Cancer Institute 2008 100(18):1280-1281; doi:10.1093/jnci/djn334
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/18/1280    most recent
djn334v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tuma, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuma, R. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

New Response Criteria Proposed for Immunotherapies

Rabiya S. Tuma

The first 10% of the full text of this article appears below.

Clinical investigators are testing the antitumor activity of several immunotherapies in a variety of malignancies. But new data from trials in melanoma patients suggest that the standard criteria used to define tumor response and progression may not adequately reflect patient responses to immunotherapeutic agents. In a worst-case scenario, researchers say, the disconnect between patient responses and the criteria used to evaluate them could cause active drugs to fail in clinical trials and the regulatory process. With these concerns in mind, a group of academic and industry researchers proposed a modification to the standard response criteria, which they presented at the annual meeting of the American Society of Clinical Oncology.

"This is important to all of us in the field," said Jedd Wolchok, M.D., director of immunotherapy clinical trials at Memorial Sloan-Kettering Cancer Center in New York and a coauthor on the proposal. "We don’t want to see . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?